TY - JOUR
T1 - Impact of New Scatter Correction Strategies on High-Resolution Research Tomograph Brain PET Studies
AU - Mansor, Syahir
AU - Boellaard, Ronald
AU - Huisman, Marc C.
AU - van Berckel, Bart N. M.
AU - Schuit, Robert C.
AU - Windhorst, Albert D.
AU - Lammertsma, Adriaan A.
AU - van Velden, Floris H. P.
PY - 2016/8
Y1 - 2016/8
N2 - Purpose
The aim of this study is to evaluate the impact of different scatter correction strategies on quantification of high-resolution research tomograph (HRRT) data for three tracers covering a wide range in kinetic profiles.
Procedures
Healthy subjects received dynamic HRRT scans using either (R)-[11C]verapamil (n = 5), [11C]raclopride (n = 5) or [11C]flumazenil (n = 5). To reduce the effects of patient motion on scatter scaling factors, a margin in the attenuation correction factor (ACF) sinogram was applied prior to 2D or 3D single scatter simulation (SSS).
Results
Some (R)-[11C]verapamil studies showed prominent artefacts that disappeared with an ACF-margin of 10 mm or more. Use of 3D SSS for (R)-[11C]verapamil showed a statistically significant increase in volume of distribution compared with 2D SSS (p < 0.05), but not for [11C]raclopride and [11C]flumazenil studies (p > 0.05).
Conclusions
When there is a patient motion-induced mismatch between transmission and emission scans, applying an ACF-margin resulted in more reliable scatter scaling factors but did not change (and/or deteriorate) quantification.
AB - Purpose
The aim of this study is to evaluate the impact of different scatter correction strategies on quantification of high-resolution research tomograph (HRRT) data for three tracers covering a wide range in kinetic profiles.
Procedures
Healthy subjects received dynamic HRRT scans using either (R)-[11C]verapamil (n = 5), [11C]raclopride (n = 5) or [11C]flumazenil (n = 5). To reduce the effects of patient motion on scatter scaling factors, a margin in the attenuation correction factor (ACF) sinogram was applied prior to 2D or 3D single scatter simulation (SSS).
Results
Some (R)-[11C]verapamil studies showed prominent artefacts that disappeared with an ACF-margin of 10 mm or more. Use of 3D SSS for (R)-[11C]verapamil showed a statistically significant increase in volume of distribution compared with 2D SSS (p < 0.05), but not for [11C]raclopride and [11C]flumazenil studies (p > 0.05).
Conclusions
When there is a patient motion-induced mismatch between transmission and emission scans, applying an ACF-margin resulted in more reliable scatter scaling factors but did not change (and/or deteriorate) quantification.
KW - Positron emission tomography (PET)
KW - High-resolution research tomograph (HRRT)
KW - Scatter correction
KW - Scatter scaling factor
KW - Patient motion
KW - Single scatter simulation
KW - ACF-margin
U2 - 10.1007/s11307-015-0921-x
DO - 10.1007/s11307-015-0921-x
M3 - Article
C2 - 26728160
VL - 18
SP - 627
EP - 635
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
SN - 1536-1632
IS - 4
ER -